{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:30:12Z","timestamp":1790220612910,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite interesting and unique pharmacological properties, levosimendan has not proven a clear superiority to placebo in the patient populations that have been enrolled in the various recent multicenter randomized controlled trials. However, the pharmacodynamic effects of levosimendan are still considered potentially very useful in a number of specific situations.<\/jats:p><jats:p>Patients with decompensated heart failure requiring inotropic support and receiving beta-blockers represent the most widely accepted indication. Repeated infusions of levosimendan are increasingly used to facilitate weaning from dobutamine and avoid prolonged hospitalizations in patients with end-stage heart failure, awaiting heart transplantation or left ventricular assist device implantation. New trials are under way to confirm or refute the potential usefulness of levosimendan to facilitate weaning from veno-arterial ECMO, to treat cardiogenic shock due to left or right ventricular failure because the current evidence is mostly retrospective and requires confirmation with better-designed studies. Takotsubo syndrome may represent an ideal target for this non-adrenergic inotrope, but this statement also relies on expert opinion. There is no benefit from levosimendan in patients with septic shock. The two large trials evaluating the prophylactic administration of levosimendan (pharmacological preconditioning) in cardiac surgical patients with poor left ventricular ejection fraction could not show a significant reduction in their composite endpoints reflecting low cardiac output syndrome with respect to placebo. However, the subgroup of those who underwent isolated CABG appeared to have a reduction in mortality. A new study will be required to confirm this exploratory finding.<\/jats:p><jats:p>Levosimendan remains a potentially useful inodilator agent in a number of specific situations due to its unique pharmacological properties. More studies are needed to provide a higher level of proof regarding these indications.<\/jats:p>","DOI":"10.1186\/s13054-019-2674-4","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T12:02:35Z","timestamp":1575028955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-6011","authenticated-orcid":false,"given":"Bernard","family":"Cholley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Fellahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Longrois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Amour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Ouattara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"2674_CR1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F Follath","year":"2002","unstructured":"Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196\u2013202.","journal-title":"Lancet."},{"key":"2674_CR2","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","volume":"23","author":"VS Moiseyev","year":"2002","unstructured":"Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422\u201332.","journal-title":"Eur Heart J"},{"key":"2674_CR3","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297:1883\u201391.","journal-title":"JAMA."},{"key":"2674_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/CCM.0b013e318232962a","volume":"40","author":"G Landoni","year":"2012","unstructured":"Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40:634\u201346.","journal-title":"Crit Care Med"},{"key":"2674_CR5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1053\/j.jvca.2013.03.027","volume":"27","author":"RW Harrison","year":"2013","unstructured":"Harrison RW, Hasselblad V, Mehta RH, Levin R, Harrington RA, Alexander JH. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2013;27:1224\u201332.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2674_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/jocs.12562","volume":"30","author":"JY Lim","year":"2015","unstructured":"Lim JY, Deo SV, Rababa'h A, Altarabsheh SE, Cho YH, Hang D, McGraw M, Avery EG, Markowitz AH, Park SJ. Levosimendan reduces mortality in adults with left ventricular dysfunction undergoing cardiac surgery: a systematic review and meta-analysis. J Card Surg. 2015;30:547\u201354.","journal-title":"J Card Surg"},{"key":"2674_CR7","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","volume":"376","author":"RH Mehta","year":"2017","unstructured":"Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, Harrison RW, Hay D, Fremes S, Duncan A, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New Engl J Med. 2017;376:2032\u201342.","journal-title":"New Engl J Med."},{"key":"2674_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2017.9973","volume":"318","author":"B Cholley","year":"2017","unstructured":"Cholley B, Caruba T, Grosjean S, Amour J, Ouattara A, Villacorta J, Miguet B, Guinet P, Levy F, Squara P, et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA. 2017;318:548\u201356.","journal-title":"JAMA."},{"key":"2674_CR9","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1616325","volume":"376","author":"G Landoni","year":"2017","unstructured":"Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, Calabro MG, Grigoryev EV, Likhvantsev VV, Salgado-Filho MF, et al. Levosimendan for hemodynamic support after cardiac surgery. New Engl J Med. 2017;376:2021\u201331.","journal-title":"New Engl J Med."},{"key":"2674_CR10","doi-asserted-by":"crossref","first-page":"28584","DOI":"10.1016\/S0021-9258(19)61945-9","volume":"269","author":"P Pollesello","year":"1994","unstructured":"Pollesello P, Ovaska M, Kaivola J, Tilgmann C, Lundstrom K, Kalkkinen N, Ulmanen I, Nissinen E, Taskinen J. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem. 1994;269:28584\u201390.","journal-title":"J Biol Chem"},{"key":"2674_CR11","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/S0022-2828(95)91371-8","volume":"27","author":"H Haikala","year":"1995","unstructured":"Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol. 1995;27:2155\u201365.","journal-title":"J Mol Cell Cardiol"},{"key":"2674_CR12","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/0022-2828(95)90009-8","volume":"27","author":"H Haikala","year":"1995","unstructured":"Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27:1859\u201366.","journal-title":"J Mol Cell Cardiol"},{"key":"2674_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0014-2999(97)01362-9","volume":"339","author":"MK Lancaster","year":"1997","unstructured":"Lancaster MK, Cook SJ. The effects of levosimendan on [Ca2+]i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol. 1997;339:97\u2013100.","journal-title":"Eur J Pharmacol"},{"key":"2674_CR14","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0009-9236(97)90139-9","volume":"61","author":"H Ukkonen","year":"1997","unstructured":"Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Nagren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther. 1997;61:596\u2013607.","journal-title":"Clin Pharmacol Ther"},{"key":"2674_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00005344-200404000-00011","volume":"43","author":"P Kaheinen","year":"2004","unstructured":"Kaheinen P, Pollesello P, Levijoki J, Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol. 2004;43:555\u201361.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2674_CR16","unstructured":"Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, Metzger J, Papp Z, Tocchetti CG, Yilmaz MB et al. Treatments targeting inotropy. Eur Heart J. 2018;00:1\u201319."},{"key":"2674_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0014-2999(97)01108-4","volume":"333","author":"H Yokoshiki","year":"1997","unstructured":"Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249\u201359.","journal-title":"Eur J Pharmacol"},{"key":"2674_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1211\/0022357001773715","volume":"52","author":"J Pataricza","year":"2000","unstructured":"Pataricza J, Hohn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol. 2000;52:213\u20137.","journal-title":"J Pharm Pharmacol"},{"key":"2674_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.bcp.2004.05.018","volume":"68","author":"DM Kopustinskiene","year":"2004","unstructured":"Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol. 2004;68:807\u201312.","journal-title":"Biochem Pharmacol"},{"key":"2674_CR20","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1152\/japplphysiol.00747.2007","volume":"103","author":"LV Zingman","year":"2007","unstructured":"Zingman LV, Alekseev AE, Hodgson-Zingman DM, Terzic A. ATP-sensitive potassium channels: metabolic sensing and cardioprotection. J Appl Physiol. 2007;103:1888\u201393.","journal-title":"J Appl Physiol"},{"key":"2674_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bja\/aen367","volume":"102","author":"L Tritapepe","year":"2009","unstructured":"Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, Singer M. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102:198\u2013204.","journal-title":"Br J Anaesth"},{"key":"2674_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5414\/CPP40465","volume":"40","author":"M Kivikko","year":"2002","unstructured":"Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002;40:465\u201371.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2674_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejheart.2006.04.012","volume":"9","author":"J Lilleberg","year":"2007","unstructured":"Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007;9:75\u201382.","journal-title":"Eur J Heart Fail"},{"key":"2674_CR24","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1056\/NEJMoa1609409","volume":"375","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, Mason AJ, Cross M, Al-Beidh F, Best-Lane J, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. New Engl J Med. 2016;375:1638\u201348.","journal-title":"New Engl J Med"},{"key":"2674_CR25","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/eurheartj\/ehr026","volume":"32","author":"G Hasenfuss","year":"2011","unstructured":"Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. Eur Heart J. 2011;32:1838\u201345.","journal-title":"Eur Heart J"},{"key":"2674_CR26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1097\/ALN.0b013e31828f4fc3","volume":"118","author":"JL Fellahi","year":"2013","unstructured":"Fellahi JL, Fischer MO, Daccache G, Gerard JL, Hanouz JL. Positive inotropic agents in myocardial ischemia-reperfusion injury: a benefit\/risk analysis. Anesthesiology. 2013;118:1460\u20135.","journal-title":"Anesthesiology."},{"key":"2674_CR27","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/00000542-199911000-00024","volume":"91","author":"JL Romson","year":"1999","unstructured":"Romson JL, Leung JM, Bellows WH, Bronstein M, Keith F, Moores W, Flachsbart K, Richter R, Pastor D, Fisher DM. Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients. Anesthesiology. 1999;91:1318\u201328.","journal-title":"Anesthesiology."},{"key":"2674_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/ALN.0b013e318173026f","volume":"108","author":"JL Fellahi","year":"2008","unstructured":"Fellahi JL, Parienti JJ, Hanouz JL, Plaud B, Riou B, Ouattara A. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology. 2008;108:979\u201387.","journal-title":"Anesthesiology."},{"key":"2674_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/ALN.0000000000000224","volume":"120","author":"DV Nielsen","year":"2014","unstructured":"Nielsen DV, Hansen MK, Johnsen SP, Hansen M, Hindsholm K, Jakobsen CJ. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score-matched analysis. Anesthesiology. 2014;120:1098\u2013108.","journal-title":"Anesthesiology."},{"key":"2674_CR30","doi-asserted-by":"publisher","unstructured":"Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev. 2005;(1):CD002230. https:\/\/doi.org\/10.1002\/14651858.CD002230.pub2","DOI":"10.1002\/14651858.CD002230.pub2"},{"key":"2674_CR31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00134-010-2073-4","volume":"37","author":"A Mebazaa","year":"2011","unstructured":"Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, Delgado JF, Follath F. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37:290\u2013301.","journal-title":"Intensive Care Med"},{"key":"2674_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.annemergmed.2009.06.512","volume":"54","author":"H Leppikangas","year":"2009","unstructured":"Leppikangas H, Ruokonen E, Rutanen J, Kiviniemi V, Lindgren L, Kurola J. Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study. Ann Emerg Med. 2009;54:811\u20137 e1\u20133.","journal-title":"Ann Emerg Med."},{"key":"2674_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/eurjhf\/hfq032","volume":"12","author":"CH Bergh","year":"2010","unstructured":"Bergh CH, Andersson B, Dahlstrom U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikstrom G. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010;12:404\u201310.","journal-title":"Eur J Heart Fail"},{"key":"2674_CR34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/eurjhf\/hfn045","volume":"11","author":"A Mebazaa","year":"2009","unstructured":"Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11:304\u201311.","journal-title":"Eur J Heart Fail"},{"key":"2674_CR35","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"2674_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijcard.2016.05.009","volume":"218","author":"MS Nieminen","year":"2016","unstructured":"Nieminen MS, Buerke M, Cohen-Solal A, Costa S, Edes I, Erlikh A, Franco F, Gibson C, Gorjup V, Guarracino F, et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. Int J Cardiol. 2016;218:150\u20137.","journal-title":"Int J Cardiol"},{"key":"2674_CR37","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1136\/hrt.2005.079707","volume":"92","author":"JT Parissis","year":"2006","unstructured":"Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, Iliodromitis E, Kremastinos DT. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart. 2006;92:1768\u201372.","journal-title":"Heart."},{"key":"2674_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cardfail.2007.04.004","volume":"13","author":"S Mavrogeni","year":"2007","unstructured":"Mavrogeni S, Giamouzis G, Papadopoulou E, Thomopoulou S, Dritsas A, Athanasopoulos G, Adreanides E, Vassiliadis I, Spargias K, Panagiotakos D, et al. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail. 2007;13:556\u20139.","journal-title":"J Card Fail"},{"key":"2674_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/FJC.0b013e31826b86aa","volume":"60","author":"G Malfatto","year":"2012","unstructured":"Malfatto G, Della Rosa F, Villani A, Rella V, Branzi G, Facchini M, Parati G. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival. J Cardiovasc Pharmacol. 2012;60:450\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2674_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijcard.2014.04.243","volume":"175","author":"T Thorvaldsen","year":"2014","unstructured":"Thorvaldsen T, Benson L, Hagerman I, Dahlstrom U, Edner M, Lund LH. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. Int J Cardiol. 2014;175:55\u201361.","journal-title":"Int J Cardiol"},{"key":"2674_CR41","doi-asserted-by":"publisher","first-page":"C8","DOI":"10.1093\/eurheartj\/sux004","volume":"19","author":"JF Delgado","year":"2017","unstructured":"Delgado JF, Oliva F, Reinecke A. The inodilator levosimendan in repetitive doses in the treatment of advanced heart failure. Eur Heart J. 2017;19:C8\u2013C14.","journal-title":"Eur Heart J"},{"key":"2674_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2015.08.188","volume":"202","author":"S Silvetti","year":"2016","unstructured":"Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: an updated meta-analysis. Int J Cardiol. 2016;202:138\u201343.","journal-title":"Int J Cardiol"},{"key":"2674_CR43","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/ejhf.118","volume":"16","author":"J Altenberger","year":"2014","unstructured":"Altenberger J, Parissis JT, Costard-Jaeckle A, Winter A, Ebner C, Karavidas A, Sihorsch K, Avgeropoulou E, Weber T, Dimopoulos L, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014;16:898\u2013906.","journal-title":"Eur J Heart Fail"},{"key":"2674_CR44","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ejhf.1145","volume":"20","author":"J Comin-Colet","year":"2018","unstructured":"Comin-Colet J, Manito N, Segovia-Cubero J, Delgado J, Garcia Pinilla JM, Almenar L, Crespo-Leiro MG, Sionis A, Blasco T, Pascual-Figal D, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20:1128\u201336.","journal-title":"Eur J Heart Fail"},{"key":"2674_CR45","doi-asserted-by":"publisher","first-page":"I11","DOI":"10.1093\/eurheartj\/suy040","volume":"20","author":"F Oliva","year":"2018","unstructured":"Oliva F, Comin-Colet J, Fedele F, Fruhwald F, Gustafsson F, Kivikko M, Borbely A, Polzl G, Tschope C. Repetitive levosimendan treatment in the management of advanced heart failure. Eur Heart J. 2018;20:I11\u201320.","journal-title":"Eur Heart J"},{"key":"2674_CR46","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jama.285.2.190","volume":"285","author":"JS Hochman","year":"2001","unstructured":"Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, Webb JG, Steingart R, Picard MH, Menegus MA, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190\u20132.","journal-title":"JAMA."},{"key":"2674_CR47","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1161\/01.CIR.0000075927.67673.F2","volume":"107","author":"JS Hochman","year":"2003","unstructured":"Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998\u20133002.","journal-title":"Circulation."},{"key":"2674_CR48","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1161\/CIRCULATIONAHA.117.029532","volume":"136","author":"S van Diepen","year":"2017","unstructured":"van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136:e232\u2013e68.","journal-title":"Circulation."},{"key":"2674_CR49","doi-asserted-by":"publisher","first-page":"C2","DOI":"10.1093\/eurheartj\/sux001","volume":"19","author":"F Gustafsson","year":"2017","unstructured":"Gustafsson F, Guarracino F, Schwinger RHG. The inodilator levosimendan as a treatment for acute heart failure in various settings. Eur Heart J (suppl). 2017;19:C2\u20137.","journal-title":"Eur Heart J (suppl)"},{"key":"2674_CR50","volume":"1","author":"J Schumann","year":"2018","unstructured":"Schumann J, Henrich EC, Strobl H, Prondzinsky R, Weiche S, Thiele H, Werdan K, Frantz S, Unverzagt S. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1:CD009669.","journal-title":"Cochrane Database Syst Rev"},{"key":"2674_CR51","first-page":"409","volume":"42","author":"M Fang","year":"2018","unstructured":"Fang M, Cao H, Wang Z. Levosimendan in patients with cardiogenic shock complicating myocardial infarction: a meta-analysis. Med Int. 2018;42:409\u201315.","journal-title":"Med Int"},{"key":"2674_CR52","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/eurheartj\/ehy077","volume":"39","author":"JR Ghadri","year":"2018","unstructured":"Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, et al. International expert consensus document on Takotsubo syndrome (part II): diagnostic workup, outcome, and management. Eur Heart J. 2018;39:2047\u201362.","journal-title":"Eur Heart J"},{"key":"2674_CR53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ejhf.424","volume":"18","author":"AR Lyon","year":"2016","unstructured":"Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, Sheppard MN, Figtree GA, Parodi G, Akashi YJ, et al. Current state of knowledge on Takotsubo syndrome: a position statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18:8\u201327.","journal-title":"Eur J Heart Fail"},{"key":"2674_CR54","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jchf.2018.10.015","volume":"7","author":"G Tavazzi","year":"2019","unstructured":"Tavazzi G, Mojoli F, Iotti GA, Via G. Does levosimendan have room in Takotsubo syndrome? JACC Heart failure. 2019;7:174.","journal-title":"JACC Heart failure"},{"key":"2674_CR55","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1097\/01.CCM.0000242157.19347.50","volume":"34","author":"F Kerbaul","year":"2006","unstructured":"Kerbaul F, Rondelet B, Demester JP, Fesler P, Huez S, Naeije R, Brimioulle S. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med. 2006;34:2814\u20139.","journal-title":"Crit Care Med"},{"key":"2674_CR56","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1097\/01.CCM.0000275266.33910.8D","volume":"35","author":"F Kerbaul","year":"2007","unstructured":"Kerbaul F, Gariboldi V, Giorgi R, Mekkaoui C, Guieu R, Fesler P, Gouin F, Brimioulle S, Collart F. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med. 2007;35:1948\u201354.","journal-title":"Crit Care Med"},{"key":"2674_CR57","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00134-011-2144-1","volume":"37","author":"LA Schwarte","year":"2011","unstructured":"Schwarte LA, Schwartges I, Thomas K, Schober P, Picker O. The effects of levosimendan and glibenclamide on circulatory and metabolic variables in a canine model of acute hypoxia. Intensive Care Med. 2011;37:701\u201310.","journal-title":"Intensive Care Med"},{"key":"2674_CR58","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/FJC.0b013e31824938f0","volume":"59","author":"A Wiklund","year":"2012","unstructured":"Wiklund A, Kylhammar D, Radegran G. Levosimendan attenuates hypoxia-induced pulmonary hypertension in a porcine model. J Cardiovasc Pharmacol. 2012;59:441\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2674_CR59","doi-asserted-by":"crossref","first-page":"204589401879090","DOI":"10.1177\/2045894018790905","volume":"8","author":"MS Hansen","year":"2018","unstructured":"Hansen MS, Andersen A, Nielsen-Kudsk JE. Levosimendan in pulmonary hypertension and right heart failure. Pulm Circ. 2018;8:2045894018790905.","journal-title":"Pulm Circ"},{"key":"2674_CR60","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1161\/01.CIR.102.18.2222","volume":"102","author":"MT Slawsky","year":"2000","unstructured":"Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators Circulation. 2000;102:2222\u20137.","journal-title":"Study Investigators Circulation"},{"key":"2674_CR61","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.amjcard.2006.06.052","volume":"98","author":"JT Parissis","year":"2006","unstructured":"Parissis JT, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K, Nikolaou M, Filippatos G, Kremastinos D. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol. 2006;98:1489\u201392.","journal-title":"Am J Cardiol"},{"key":"2674_CR62","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1097\/CCM.0b013e3181b0314a","volume":"37","author":"MA Russ","year":"2009","unstructured":"Russ MA, Prondzinsky R, Carter JM, Schlitt A, Ebelt H, Schmidt H, Lemm H, Heinroth K, Soeffker G, Winkler M, et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med. 2009;37:3017\u201323.","journal-title":"Crit Care Med"},{"key":"2674_CR63","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s00059-008-3051-2","volume":"33","author":"G Poelzl","year":"2008","unstructured":"Poelzl G, Zwick RH, Grander W, Metzler B, Jonetzko P, Frick M, Ulmer H, Pachinger O, Roithinger FX. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz. 2008;33:368\u201373.","journal-title":"Herz."},{"key":"2674_CR64","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/j.jacc.2014.03.046","volume":"63","author":"D Abrams","year":"2014","unstructured":"Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63:2769\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"2674_CR65","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13613-015-0094-4","volume":"5","author":"B Levy","year":"2015","unstructured":"Levy B, Bastien O, Karim B, Cariou A, Chouihed T, Combes A, Mebazaa A, Megarbane B, Plaisance P, Ouattara A, et al. Experts\u2019 recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care. 2015;5:52.","journal-title":"Ann Intensive Care"},{"key":"2674_CR66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119\u201377.","journal-title":"Eur Heart J"},{"key":"2674_CR67","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/MAT.0b013e3182a4b32e","volume":"59","author":"A Affronti","year":"2013","unstructured":"Affronti A, di Bella I, Carino D, Ragni T. Levosimendan may improve weaning outcomes in venoarterial ECMO patients. ASAIO J. 2013;59:554\u20137.","journal-title":"ASAIO J"},{"key":"2674_CR68","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1053\/j.jvca.2016.03.139","volume":"30","author":"F Sangalli","year":"2016","unstructured":"Sangalli F, Avalli L, Laratta M, Formica F, Maggioni E, Caruso R, Cristina Costa M, Guazzi M, Fumagalli R. Effects of levosimendan on endothelial function and hemodynamics during weaning from veno-arterial extracorporeal life support. J Cardiothorac Vasc Anesth. 2016;30:1449\u201353.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2674_CR69","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/bja\/aew151","volume":"117","author":"K Distelmaier","year":"2016","unstructured":"Distelmaier K, Roth C, Schrutka L, Binder C, Steinlechner B, Heinz G, Lang IM, Maurer G, Koinig H, Niessner A, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth. 2016;117:52\u20138.","journal-title":"Br J Anaesth"},{"key":"2674_CR70","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1053\/j.jvca.2018.04.019","volume":"32","author":"A Jacky","year":"2018","unstructured":"Jacky A, Rudiger A, Kruger B, Wilhelm MJ, Paal S, Seifert B, Spahn DR, Bettex D. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery-a retrospective before-and-after study. J Cardiothorac Vasc Anesth. 2018;32:2112\u20139.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2674_CR71","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13613-019-0503-1","volume":"9","author":"S Vally","year":"2019","unstructured":"Vally S, Ferdynus C, Persichini R, Bouchet B, Braunberger E, Lo Pinto H, Martinet O, Vandroux D, Aujoulat T, Allyn J, et al. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intensive Care. 2019;9:24.","journal-title":"Ann Intensive Care"},{"key":"2674_CR72","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1097\/01.CCM.0000261889.18102.84","volume":"35","author":"D Barraud","year":"2007","unstructured":"Barraud D, Faivre V, Damy T, Welschbillig S, Gayat E, Heymes C, Payen D, Shah AM, Mebazaa A. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med. 2007;35:1376\u201382.","journal-title":"Crit Care Med"},{"key":"2674_CR73","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s00134-019-05731-w","volume":"45","author":"DB Antcliffe","year":"2019","unstructured":"Antcliffe DB, Santhakumaran S, Orme RML, Ward JK, Al-Beidh F, O'Dea K, Perkins GD, Singer M, McAuley DF, Mason AJ, et al. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Med. 2019;45:1392\u2013400.","journal-title":"Intensive Care Med"},{"key":"2674_CR74","doi-asserted-by":"publisher","unstructured":"van Diepen S, Mehta RH, Leimberger JD, Goodman SG, Fremes S, Jankowich R, Heringlake M, Anstrom KJ, Levy JH, Luber J, Nagpal AD, Duncan AE, Argenziano M, Toller W, Teoh K, Knight JD, Lopes RD, Cowper PA, Mark DB, Alexander JH. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. J Thorac Cardiovasc Surg. 2019;S0022-5223(19)31278-4. https:\/\/doi.org\/10.1016\/j.jtcvs.2019.06.020. [Epub ahead of print]","DOI":"10.1016\/j.jtcvs.2019.06.020"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-019-2674-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13054-019-2674-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-019-2674-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T19:23:22Z","timestamp":1612725802000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-019-2674-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2674"],"URL":"https:\/\/doi.org\/10.1186\/s13054-019-2674-4","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"assertion":[{"value":"22 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are members of an advisory board working for Orion Pharma and have received honoraria from the Company for their participation to the board and for giving invited lectures at industry symposia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"385"}}